




Searching News Database: TYSABRI
HSMN NewsFeed - 8 Mar 2017
Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women's Rogaine(R) Foam
Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women's Rogaine(R) Foam
HSMN NewsFeed - 1 Mar 2017
Perrigo Announces FDA Final Approval For The Generic Version Of Axiron(R) Topical Solution, 30 mg/1.5 mL
Perrigo Announces FDA Final Approval For The Generic Version Of Axiron(R) Topical Solution, 30 mg/1.5 mL
HSMN NewsFeed - 17 Feb 2017
Perrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution
Perrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution
HSMN NewsFeed - 24 Jan 2017
Perrigo Announces FDA Approval Of Its First-To-File AB Rated Generic Version Of Topicort(R) Spray, 0.25%
Perrigo Announces FDA Approval Of Its First-To-File AB Rated Generic Version Of Topicort(R) Spray, 0.25%
HSMN NewsFeed - 21 Jun 2016
Perrigo Announces FDA Clearance And Launch Of Non-GMO* Infant Formulas For The U.S. Store Brand Market
Perrigo Announces FDA Clearance And Launch Of Non-GMO* Infant Formulas For The U.S. Store Brand Market
HSMN NewsFeed - 2 May 2016
Perrigo Announces FDA Approval and Launch of the Generic Version of BenzaClin(R) Pump Topical Gel
Perrigo Announces FDA Approval and Launch of the Generic Version of BenzaClin(R) Pump Topical Gel
HSMN NewsFeed - 10 Nov 2015
Perrigo Announces FDA Approval Of The AB Rated Generic Version Of KlorCon(R) Extended-Release Tablets
Perrigo Announces FDA Approval Of The AB Rated Generic Version Of KlorCon(R) Extended-Release Tablets
HSMN NewsFeed - 28 Aug 2015
Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction
Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction
HSMN NewsFeed - 27 Apr 2015
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
HSMN NewsFeed - 29 Sep 2014
Lumara Health(TM) to be Acquired in Two Separate Transactions for up to $1.107 Billion
Lumara Health(TM) to be Acquired in Two Separate Transactions for up to $1.107 Billion
HSMN NewsFeed - 30 Jan 2014
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
HSMN NewsFeed - 5 Jan 2011
Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
HSMN NewsFeed - 7 Jan 2010
Lycera Appoints Senior Life Sciences Executive William J. Sibold as President and CEO
Lycera Appoints Senior Life Sciences Executive William J. Sibold as President and CEO
HSMN NewsFeed - 2 Dec 2009
Seasoned Clinical Development Expert Joins Opexa to Lead Tovaxin(R) Development in Multiple Sclerosis
Seasoned Clinical Development Expert Joins Opexa to Lead Tovaxin(R) Development in Multiple Sclerosis
HSMN NewsFeed - 25 Feb 2009
Elan Announces Further Alignment of Resources as Part of On-Going Strategic Review Process
Elan Announces Further Alignment of Resources as Part of On-Going Strategic Review Process
HSMN NewsFeed - 5 Sep 2008
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
HSMN NewsFeed - 22 Jul 2008
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
HSMN NewsFeed - 14 Jan 2008
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
HSMN NewsFeed - 23 Jul 2007
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
HSMN NewsFeed - 18 Jun 2007
Oculus Innovative Sciences Appoints Vice President of Regulatory Affairs and Quality
Oculus Innovative Sciences Appoints Vice President of Regulatory Affairs and Quality
HSMN NewsFeed - 24 Jan 2007
Teva Files Patent Infringement Complaints Regarding Sertraline Hydrochloride
Teva Files Patent Infringement Complaints Regarding Sertraline Hydrochloride
HSMN NewsFeed - 22 Dec 2006
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
HSMN NewsFeed - 21 Nov 2006
Teva Announces Agreement with Pfizer Regarding Idarubicin, Azithromycin, and Epirubicin
Teva Announces Agreement with Pfizer Regarding Idarubicin, Azithromycin, and Epirubicin
HSMN NewsFeed - 16 Oct 2006
Teva Announces OxyContin(R) Litigation Dismissed; Settlement with Purdue Finalized
Teva Announces OxyContin(R) Litigation Dismissed; Settlement with Purdue Finalized
HSMN NewsFeed - 2 Oct 2006
COPAXONE(R) Showed Sustained Benefit on Slowing Brain Tissue Damage in Multiple Sclerosis Patients
COPAXONE(R) Showed Sustained Benefit on Slowing Brain Tissue Damage in Multiple Sclerosis Patients
HSMN NewsFeed - 21 Aug 2006
Teva Announces Health Canada Approves AZILECT(R) (Rasagiline) for Parkinson's Disease
Teva Announces Health Canada Approves AZILECT(R) (Rasagiline) for Parkinson's Disease
HSMN NewsFeed - 12 Jul 2006
Teva Will Be Sole Promoter of AZILECT(R) for Parkinson's Disease in the United States
Teva Will Be Sole Promoter of AZILECT(R) for Parkinson's Disease in the United States
HSMN NewsFeed - 23 Jun 2006
Teva Announces Novartis' Sandoz Unit Seeks to Delay First FDA Approval of Generic Zocor(R)
Teva Announces Novartis' Sandoz Unit Seeks to Delay First FDA Approval of Generic Zocor(R)
HSMN NewsFeed - 22 Jun 2006
Court of Appeals Rules in Favor of Teva on Biaxin(R) XL Preliminary Injunction
Court of Appeals Rules in Favor of Teva on Biaxin(R) XL Preliminary Injunction
HSMN NewsFeed - 14 Jun 2006
Teva Announces Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets
Teva Announces Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets
HSMN NewsFeed - 5 Jun 2006
FDA Approves the Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
FDA Approves the Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
HSMN NewsFeed - 17 May 2006
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
HSMN NewsFeed - 17 May 2006
Teva Announces FDA Grants Approval of AZILECT(R) (Rasagiline) for Parkinson's Disease
Teva Announces FDA Grants Approval of AZILECT(R) (Rasagiline) for Parkinson's Disease
HSMN NewsFeed - 1 May 2006
District Court Grants Teva Summary Judgment for Generic Zocor(R) Exclusivity
District Court Grants Teva Summary Judgment for Generic Zocor(R) Exclusivity
HSMN NewsFeed - 28 Apr 2006
CHMP Issues Positive Opinion for TYSABRI(R) as a Treatment for Relapsing-Remitting Multiple Sclerosis
CHMP Issues Positive Opinion for TYSABRI(R) as a Treatment for Relapsing-Remitting Multiple Sclerosis
HSMN NewsFeed - 29 Mar 2006
Biogen Idec and Elan Announce Re-Initiation of TYSABRI(R) Clinical Trial Dosing in Multiple Sclerosis
Biogen Idec and Elan Announce Re-Initiation of TYSABRI(R) Clinical Trial Dosing in Multiple Sclerosis
Additional items found! 29

Members Archive contains
29 additional stories matching:
TYSABRI
(Password required)
TYSABRI
(Password required)